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REVERSAL OF HEPARIN 
ANTICOAGULATION BY 
RECOMBINANT PLATELET 
FACTOR 4 AND PROTAMINE 
SULFATE IN BABOONS 
DURING CARDIOPULMONARY 
BYPASS 
The ability of recombinant platelet factor 4 and protamine to neutralize heparin 
after cardiopulmonary bypass was compared in anesthestized baboons. Clotting 
titration curves of heparinized baboon blood demonstrate an anticoagulant effect of 
protamine that is not seen with recombinant platelet factor 4. Neither drug caused 
meaningful changes in central pressures or cardiac output within 30 minutes after 
injection. After 30 minutes of cardiopulmonary bypass, recombinant platelet factor 
4 normalized thrombin times and activated partial thromboplastin times within 5 
minutes of injection, but protamine did not. Neither drug altered bleeding times. 
Recombinant platelet factor 4 caused a species-specific leukopenia in baboons and 
significantly increased activated complement protein 3 (C3a) more than protamine. 
However, the increase in plasma C3a was small and neither drug caused a 
significant increase in plasma neutrophil elastase-oq proteinase inhibitor complex. 
We conclude that recombinant platelet factor 4 is etfective and safe in baboons, does 
not have an anticoagulant effect with excess concentration, and reverses in vivo heparin 
more rapidly than protamine. The data support progression to a clinical trial. 
(J THORAC CARDIOVASC SURG 1995;109:765-71) 
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p rotamine sulfate is universally used to neutralize 
heparin after cardiopulmonary bypass (CPB), 
but it is associated with a high incidence of adverse 
reactions. 1-3 The protamine-heparin complex acti- 
vates complement by the classic pathway 4'5 and 
generates the anaphylatoxins C3a, C4a, and C5a. s 
These vasoactive peptides or possible histamine 
release (or both) 6' 7 may cause transient hypotension 
From the Division of Cardiothoracic Surgery, Harrison Depart- 
ment of Surgery, School of Medicine, University of Pennsyl- 
vania, Philadelphia, Pa. 
Supported by HL 47186 and 47456 from the National Heart, 
Lung, and Blood Institute, National Institutes of Health, 
Bethesda Md. 
Read at the Seventy-fourth Annual Meeting of The American 
Association for Thoracic Surgery, New York, N.Y., April 
24-27, 1994. 
Address for reprints: L. Henry Edmunds, Jr.  MD, Division of 
Cardiothoracic Surgery, Hospital of the University of Penn- 
sylvania, 3400 Spruce St., Philadelphia, PA 19104. 
*Repligen Corp., Kendall Square, Mass. 
**Sol Sherry Thrombosis Research Center and Department of
Physiology, Temple University School of Medicine, Philadel- 
phia, Pa. 
Copyright © 1995 by Mosby-Year Book, Inc. 
0022-5223/95 $3.00 + 0 12/6/62467 
that occurs 30 to 150 seconds after injection in 
approximately half of patients,  Other adverse reac- 
tions, which are occasionally life-threatening or fa- 
tal, involve immunoglobulin G and immunoglobulin 
E antibodies 8 or synthesis and release of thrombox- 
ane A 2 by platelets and pulmonary macrophages. 9' 10 
Platelet factor 4 (PF4) is a protein stored in 
platelet a-granules. The protein contains 70 
amino acids (molecular weight = 7800) and binds 
with high affinity to heparin (see reference 11 for 
references). In contrast o the ionic bond between 
positively charged protamine and negatively 
charged heparin, PF4 binds and neutralizes hep- 
arin by means of a specific binding site at the 
C-terminus of PF4. ~1 PF4-heparin complex is 
cleared by liver and kidney. 12 Recombinant PF4 
(rPF4) is expressed as a fusion protein in Esche- 
richia coli and has the same amino acid composi- 
tion and terminal sequence as native PF4 after 
chemical cleavage and purification. 13 Cook and 
associates 14demonstrated that rPF4 reverses hep- 
arin anticoagulation i rats without the adverse 
effects of protamine sulfate. Both rPF4 and pro- 
tamine sulfate reverse heparin anticoagulation i
the rat and affect heparin plasma clearance simi- 
larly; however, in contrast o rPF4, elevated levels 
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of protamine sulfate induce paradoxical anticoag- 
ulation. 1» 
We compared the efficacy, safety, and side-effects 
of rPF4 and protamine for neutralizing heparin in 
baboons with and without CPB. 
Methods 
Nine young adult female baboons (Papio anubis) were 
used in 24 studies. The experimental protocol was ap- 
proved by the Institutional Animal Care and Use Com- 
mittee of the University of Pennsylvania (IACUC No. 
M-900618). After an overnight fast, the animals were 
sedated with ketamine (10 mg/kg intramuscularly), anes- 
thesia was induced with thiopental (2.0 mg/kg intrave- 
nously), and the animals were intubated. Anesthesia was 
maintained with 1.5% to 2.0% isoflurane. Heart rate, 
arterial blood pressure, and rectal temperatures were 
continuously monitored by electrocardiogram (ES-1000, 
Gould Inc., Cleveland, Ohio), femoral arterial catheter, 
and rectal probe. A second femoral arterial catheter was 
placed for blood samples. Pulmonary arterial and central 
venous pressures were measured continuously (5F Swan- 
Ganz catheter; Baxter Healthcare Corp., Edwards Divi- 
sion, Santa Ana, Calif.); pulmonary capillary wedge pres- 
sure and thermodilution cardiac outpnt (in triplicate) 
(Oximetrix 3 SO2/CO computer, Abbott Laboratories, 
North Chicago, Ill.) were measured intermittently. 
Clotting time titration curves were performed by means 
of activated partial thromboplastin times (Organon 
Teknika Corp., Durham N.C.) to determine the effects of 
various doses of protamine (Elkins-Sinn Corp., Cherry 
Hill, N.J.) and rPF4 (Repligen Corp., Kendall Square, 
Mass.) to neutralize heparin in baboon plasma. 
In 13 trials without CPB, heparin (100 U/kg intrave- 
nously; porcine intestinal, Elkins-Sinn Corp.) was given, 
followed after 5 to 10 minutes by either protamine (1 
mg/kg intravenously, n = 7) or rPF4 (2 mg/kg intrave- 
nously, n = 6). Hemodynamic measurements and blood 
samples for hematocrit value, white count, platelet count, 
platelet aggregation, and activated clotting time were 
obtained before heparin, after heparin, and 5 and 30 
minutes after protamine or rPF4. Template bleeding 
times were measured before heparin, after heparin, and 
after neutralization. 
In 12 additional trials under sterile conditions, anesthe- 
tized baboons received heparin (300 U/kg, intravenously) 
and were cannulated for partial CPB. Incisions were made 
over the right jugular vein and a femoral artery. Under 
direct vision, a catheter (8F to 10F, Medtronic Bio- 
Medicus, Eden Prairie, Minn.) was inserted over a wire 
into the right atrium. A similar 8F catheter was inserted 
into the femoral artery. The perfusion circuit had a 
surface area of 0.9 m 2 and consisted of a roller pump, 0.8 
m 2 spiral coil membrane oxygenator (Avecor Inc., Ply- 
mouth, Minn.), polyvinyl chloride venous reservoir, poly- 
carbonate connectors, and a/4-inch inner diameter silicone 
rubber tubing. The oxygenator was ventilated with 95% 
oxygen and 5% carbon dioxide at a rate of 2 L/min. The 
circuit was primed with 350 ml Normosol-R solution. Flow 
rate was 50 tal/kg per minute at 37°C for 30 minutes. 
Normal saline solution (3:1 volume) was given to replace 
blood samples and shed blood. At the end of CPB either 
protamine sulfate (3 mg/kg) or rPF4 (6 mg/kg) was given 
to reverse the anticoagulant effect of heparin. 
The electrocardiogram, systemic and pulmonary arte- 
rial pressures, central venous pressure, and rectal temper- 
ature were monitored continuously as described earlier. 
Pulmonary capillary wedge pressure and triplicate ther- 
modilution cardiac output measurements were made be- 
fore heparin, just before stopping CPB, 10 minutes before 
heparin neutralization, and 5 and 30 minutes after neu- 
tralization of heparin. Template bleeding times and blood 
samples for hematocrit value, white cell count, platelet 
count, platelet aggregation, plasma /3-thromboglobulin 
(BTG), activated clotting time, thrombin time, partial 
thromboplastin time, C3a des-Arg, and neutrophil elas- 
tase-al proteinase inhibitor complex were obtained at the 
same times. 
Hematocrit value was determined by centrifugation. 
Platelet and white ceU counts were performed within a 
hemocytometer under phase microscopy. The percentages 
of circulating leukocyte subpopulations were determined 
by performing a differential cell count of 100 cells and a 
Wright-stained peripheral blood smear. Activated clotting 
time was measured in a chronometer (Chrono-Log Inc., 
Havertown, Pa.). Activated partial thromboplastin time 
was measured with a Coag-a-mate X2 and automated 
activated partial thromboplastin time reagent (Organon 
Teknika Corp.). Thrombin time was measured with 
Thromboquik reagent (Organon Teknika Corp.) and a 
fibrometer, according to the manufacturer's in tructions. 
Template bleeding times (Simplate II, Organon Teknika 
Corp.) in duplicate were measured using the shaved 
ventral surface of the forearm and a blood pressure cuff at 
40 mm Hg. Complement activation was determined by 
measuring plasma levels of C3a des-Arg, a stable metab- 
olite of C3a, by radioimmunoassay (Amersham Corp., 
Arlington Heights, Ill). Plasma neutrophil elastase-a 1 
antitrypsin complex was measured by enzyme-linked im- 
munosorbent assay (Merck immunoassay, EM Sciences, 
Gibbsboro, N.J.). Plasma BTG was measured with recom- 
binant neutrophil activating peptide 2, a derivative of 
BTG, with tyrosine inserted at the C-terminal end (Repli- 
gen Corp.) as a tracer. The tracer had the same antigenic 
reactivity as original BTG. 
Platelet-rich plasma and platelet-poor plasma were 
prepared by differential centrifugation at 150 g for 10 
minutes and 13,600 g for 5 minutes, respectively. Platelet 
aggregation studies in platelet-rich plasma (platelet count 
was adjusted to 150,000 /xl 1 by dilution with platelet- 
poor plasma) were performed in an aggregometer (model 
340, Chrono-Log Inc.) The threshold ose of adenosine 
diphosphate (i.e., the lowest dose of agonist able to 
produce irreversible aggregation of at least 60% light 
transmission of platelet-poor plasma in 5 minutes) was 
determined. The same dose of adenosine diphosphate was 
used to determine percent aggregation of baboon plate- 
lets in all subsequent samples. Results are reported as a 
percentage of the normalized 100% control sample in 
arbitrary light transmission units. 
For calcium mobilization studies baboon and human 
neutrophils were isolated and loaded with fura 2.16 Mo- 
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Fig. 1. Clotting time titration curves (partial thromboplastin mes) after reversal of heparin anticoagu- 
lation in vitro (A) or heparinized baboon blood ex vivo (B). A, Protamine or rPF4 was added in the doses 
indicated to citrated baboon plasma containing a heparin concentration f 0.6 units/ml. B, A heparin dose 
of 300 units/kg body weight was injected intravenously into a baboon; five minutes later blood was drawn 
into citrate and neutralized with indicated oses of each drug. 
bilization of cytosolic alcium was tested by the method of 
Grynkiewicz, Poenie, and TsienJ 7 
Statistics. Data from both trials were compared by 
two-way analysis of variance with the Bonferroni correc- 
tion and paired Student's t statistic for within- and be- 
tween-group comparisons after CPB and at 5 and 30 
minutes after neutralization. 
Results 
Baboon plasma appears to be at least two times 
more sensitive to heparin than human or rat plasma 
(data not shown). Fig. 1, A shows that baboon 
plasma containing a heparin concentration of 0.6 
units/ml clots in 220 seconds. Reversal of heparin 
anticoagulation (clotting time below 50 seconds) 
occurs at protamine sulfate concentrations between 
62 and 125 /xg/ml or rPF4 concentrations between 
125 and 1000 /xg/ml. These data are consistent 
with our previous observations in human and rat 
plasma;a2,13 neutralizing concentrations of rPF4 are 
twice those of protamine sulfate. In contrast to 
protamine sulfate, however, an excess of rPF4 does 
not produce any anticoagulant effect. 
Fig. 1, B shows the effect of protamine sulfate and 
rPF4 on the partial thromboplastin time of baboon 
plasma after the animal received a heparin dose of 
300 units/kg. Clotting times are plotted against 
various concentrations of protamine and rPF4. The 
calculated heparin concentration is 37.5/xg/ml; this 
concentration of protamine completely neutralizes 
this amount of heparin, but higher concentrations 
produce an anticoagulant effect. Considerably 
higher concentrations of PF4 are needed to neutral- 
ize heparin, but rPF4 does not show any anticoagu- 
lant effect at high concentrations. 
Data from initial studies without CPB show only a 
few differences between drugs. Both drugs restore 
activated clotting times to the normal range within 5 
minutes. Protamine causes significant (p < 0.05) 
decreases in mean systemic (73.9 _+ 5.0 to 64.5 +_ 4.0 
mm Hg) and pulmonary arterial (15.0 + 1.7 to 
13.6 +_ 1.0 mm Hg) pressures and pulmonary capil- 
lary wedge (10.4 _+ 1.6 to 9.0 -2-_ 1.0 mm Hg) 
pressures 5 minutes after injection. Systemic hypo- 
tension after protamine persists for at least 30 
minutes and is significantly different from the results 
after rPF4 (p < 0.01). Both drugs cause a temporary 
decrease in leukocyte count at 5 minutes, and the 
decrease after rPF4 (9833 + 1127 to 2791 _+ 395) is 
significantly greater than after protamine. Other 
changes and differences are not significant within or 
between groups. 
In vitro neutrophil calcium mobilization tests 16' 17 
were done to explain the leukopenia fter injection 
of rPF4 in baboons, rPF4 slightly, but significantly, 
7 6 8 Bernabei et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
April 1995 
1400 
1200 
A 1000 
E 
• _o 8oo  
600 ._o 
0 
t~ 
o 400 
200 
NAP-2 
0 
Fig. 2. In vitro calcium mobilization study for baboon and human neutrophils. Recombinant human 
neutrophil activating peptide 2 (NAP2) (Repligen Corp.) has potent neutrophil activating properties 15' a7 
and served as a control, rPF4 significantly iucreases baboon eutrophil calcium, but does not change human 
neutrophil calcium, rNAP-2 dramatically increases leukocyte calcium in both species. Open bars, Baboon 
neutrophils; haded bars, human neutrophils. Values are mean -+ standard error. *p < 0.05 between 
protamiue and rPF4. **p < 0.05 within groups as compared with control values. 
mobilizes calcium in baboon, but not human, neu- 
trophils (Fig. 2). Neutrophils of both species re- 
spond similarly to recombinant eutrophil activating 
peptide 2.18 
After CPB, both drugs caused systemic hypoten- 
sion at borderline significance (p = 0.06), but this 
hypotension persisted and reaehed statistical signif- 
icance in protamine-treated animals (Table I). At 5 
minutes, both drugs normalized activated clotting 
times, but only rPF4 normalized partial thrombo- 
plastin and thrombin times (Fig. 3). The inability of 
protamine to completely neutralize heparin imme- 
diately was due to its anticoagulant effect, as dem- 
onstrated by protamine and rPF4 titration of hepa- 
rinized baboon plasma (Fig. 1, A and B). Both drugs 
caused a transient leukopenia t 5 minutes, and both 
drugs significantly increased plasma C3a. The in- 
crease after rPF4 was slightly greater than the 
increase after protamine at both times. However, 
release of neutrophil elastase-a a proteinase inhibi- 
tor complex was the same in both groups and did not 
increase after either drug. Neither drug had any 
effect on platelet count. Baboon platelets were less 
responsive to thrombin, adenosine diphosphate, and 
collagen than were human platelets (data not 
shown). Unlike human beings, baboons did not have 
an increase in plasma BTG during CPB. Bleeding 
times increased after CPB but were not affected by 
either drug. 
Diseussion 
This study demonstrates the efficacy and safety of 
rPF4 for neutralizing heparin after CPB in baboons. 
rPF4 more rapidly reverses thrombin and partial 
thromboplastin times than does protamine and in 
contrast o protamine does not have an anticoagu- 
lant effect in excess doses. As observed in rats, a5 the 
slower antiheparin effect of protamine may be due 
to the anticoagulant effect of the drugs or to slower 
' inhibition of the anti-factor Xa effect of heparin. 19 
Neither drug affects platelets; therefore, bleeding 
times remain elevated after CPB with both. 
In baboons both drugs cause a transient leukope- 
nia that is more profound with rPF4. This leukope- 
nia does not occur in the rat. 14 To explain the 
rPF4-induced neutropenia n baboons, we examined 
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Table I. Changes in hemodynamics and blood constituents during CPB in baboons 
Before heparin CPB After CPB Five minutes Thirty minutes 
Mean SAP (mm Hg) 
PS 71.2 _+ 3.9 70.3 + 5.8 63.6 + 3.2 63.1 + 3.3* 
rPF4 69.6 + 6.1 64.8 + 4.2 59.8 + 5.2 63.1 + 4.1 
Mean PAP (mm Hg) 
PS 12.8 _+ 1 13.6 + 1.8 13.6 _+ 1.6 11.8 _+ 1.1 
rPF4 13 + 0.8 13.4 _+ 0.9 13.4 +_ 1.1 12.9 _+ 0.9 
CVP (mm Hg) 
PS 4.7 -+ 1.7 6.6 +- 2.3 5.9 -+ 3.0 4.1 -+ 2.0* 
rPF4 5.2 -- 2.5 6.3 -- 3.2 6.0 -+ 2.7 5.5 -+ 2.7 
PCWP (mm Hg) 
PS 10.4 -+ 4.5 10.6 +- 4.1 10.3 - 3.7 8.3 +- 2.6 
rPF4 9.2 -+ 2.3 11.0 + 4.1 9.5 -+ 2.4 9.7 + 2.1 
Cardiac output (L/min) 
PS 1.8 4- 0.2 1.5 -+ 0.2 1.6 +- 0.2 1.4 _+ 0.2 
rPF4 1.7 + 0.2 1.6 + 0.1 1.6 + 0.1 1.5 -+ 0.1 
Activated clotting time (sec) 
PS 96 --- 2 467 - 12 409 - 13 115 + 3* 118 -+ 6.2* 
rPF4 99 _+ 3 446 +- 18 394 -- 19 117 _+ 6* 115 -- 7* 
Thrombin time (sec) 
PS 11.2 -+ 0.5 180 + 0 180 -+ 0 88 _+ 25.2"t 13.5 -+ 0.7* 
rPF4 11.2 _+ 0.3 180 _+ 0 180 _+ 0 12.6 _+ 0.4* 12.6 _+ 0.6* 
PTT (sec) 
PS 35.4 -+ 1.5 150 + 0 150 + 0 106.6 _+ 11.6"t 45.4 -+ 2.9* 
rPF4 35.3 -+ 2.4 150 _+ 0 150 _+ 0 42 +_ 4.7* 41.3 _+ 2.0* 
Platelet count (Plts/~xl) × 1000 
PS 254 -+ 13.6 192.1 -+ 20.8 187.7 -+ 19.7 172.9 + 12.3 183.3 + 18.2 
rPF4 273.8 -+ 17.4 197.3 -+ 17.5 196.5 + 17.9 184.8 +_ 17.4" 211.8 _+ 19.4" 
Platelet aggregation (% of maximum) 
PS 60 +- 3.4 65.9 -+ 3.3 64.6 -+ 1.6 59.1 -+ 4 65.3 -+ 3.2 
rPF4 66.9 _+ 4.6 62.1 -+ 4.4 56.3 _+ 4.3 53.5 _+ 4.1 58.8 + 2.9 
BTG (ng/ml) 
PS 131 -+ 16 134 -+ 7.8 108 -+ 13 105 -+ 12 79 -+ 10"$ 
rPF4 + 121 _+ 19 121 _+ 19 128 _+ 13 108 _+ 11 114 _+ 13 131 + 14 
Bleeding time (min) 
PS 4.5 _+ 0.3 12.1 _+ 2.4 11.9 _+ 2.4 
PF4 4.3 +- 0.2 15.2 _+ 2.6 15.1 _+ 1.4 
Hematocrit (%) 
PS 35.4 _+ 0.7 26.4 _+ 0.8 28.1 -- 0.9 28.4 _+ 0.8 29.7 -- 1" 
PF4 36.2 +- 1.5 27.5 +- 1.5 29.2 -+ 2.1 28.7 -+ 1.7 30.2 _+ 2.2 
C3a (ng/ml) 
PS 76 -+ 5.7 104.9 +_ 8.2 72 _+ 4.2 99.4 _+ 5.5"~ 84 +_ 6.2"t 
PF4 89.7 +- 13.2 118.7 -+ 8.5 91.3 -+ 7.7 150 -+ 3.5* 118.7 -+ 3* 
Elastase-a I proteinase inhibitor complex (txg/ml) 
PS 5.45 _+ 0.58 5.69 +_ 0.76 5.28 +_ 0.72 5.53 _+ 0.86 5.51 -+ 0.62 
PF4 3.84 _+ 0.46 5.43 _+ 0.36 6.09 _+ 0.68 6.27 _+ 0.64 6.38 _+ 0.97 
White count (cells/~l) x 1000 
PS 6.7 -+ 2.1 4.0 _+ 1.0 6.7 -+ 0.8 3.9 -+ 0.9* 7.3 +_ 0.6 
PF4 4.6 + 1.1 3.7 +- 0.9 5.6 -+ 0.7 2.1 _+ 0.3* 7.6 _+ 0.6 
Values are means -+ standard errors before, during, and after cardiopulmonary b pass (CPB). Five minutes and thirty minutes refer to times after heparin 
neutralization. SAP, Systemic arterial pressure; PAP, pulmonary artery pressure; CVP, central venous pressure; PCWP, pulmonary capillary wedge pressure; 
PTZ, partial thromboplastin time; BTG, /3-thromboglobulin; PS, protamine sulfate (n = 6); rPF4, recombinant platelet factor 4 (n = 6). 
*p < 0.05 within-group value compared with After CPB value. 
tp < 0.05 for between-group values. 
Sp < 0.01 for between-group values. 
the effect of rPF4 on the mobilization of cytosolic 
caMum in baboon and human neutrophils, rPF4 (3 
/zmol/L) did not increase calcium mobilization in 
human neutrophils but caused a slight, but signifi- 
cant, mobilization of calcium in baboon neutrophils. 
Neutrophils of both species showed the same sensi- 
tivity to neutrophil activating peptide 2 (Fig. 2). 
Because infusion of interleukin-8 (IL-8) in baboons 
7 7 0 Bernabei et aL 
The Journal of Thoracic and 
Cardiovascular Surgery 
April 1995 
Seconds 
180 
160 
140 
120 
100 
80 
60 
40 
20 
160 
140 
120 
100 
Seconds 80 
60 
40 
20 
0 
Pre- CPB After 5 30 
Hep CPB Min Min 
PRE- CPB AFTER 5 MIN 30 MIN 
HEP CPB 
Fig. 3. Thrombin times and partial thromboplastin imes before and after heparin neutralization by 
protamine (solid bars) and rPF4 (lighter bars) after CPB in baboons. A, Thrombin times. B, Partial 
thromboplastin mes. Statistics appear in Table I. 
causes atransient neutropenia 2° and because human 
rPF4 substituted with three amino acids (Glu-Leu- 
Arg) at its N-terminus activates neutrophils ina similar 
manner to IL-8, 21 the neutropenia n baboons may 
result f-rom the effect of human rPF4 on baboon IL-8 
receptors. The data suggest that rPF4-induced leuko- 
penia is species pecific, acts via IL-8 neutrophil recep- 
tors, and is unlikely to cause leukopenia in human 
beings, rPF4 in baboons also increases plasma C3a 
more than does protamine. The actual amount of 
increase is not great and neutrophil elastase does not 
increase appreciably with either drug. The impact of 
rPF4 neutralization f heparinized human blood on 
C3a generation cannot be inferred from this study. In 
heparinized rats protamine causes letLkopenia, throm- 
bocytopenia, significant activation of complement, and 
pulmonary interstitial edema, but rPF4 does not alter 
any of these parameters. 14 
Although this form of rPF4 has an amino acid 
sequence identical to that of the native peptide, the 
possibility of antibody formation and subsequent 
anaphylaxis with reexposure cannot be ruled out. 
Recently antibodies to heparin-PF4 complexes have 
been described in patients with heparin-associated 
thrombocytopenia. 22 This concern and that of com- 
plement activation taust be resolved in human trials. 
From this study we conclude that rPF4 effectively 
neutralizes heparin after CPB and acts faster than 
does protamine, rPF4 does not have an anticoagu- 
lant effect with excess concentrations. The drug does 
not affect cardiac function or platelets, but does 
mildly activate complement. The data support a 
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clinical trial to resolve concerns raised by possible 
complement activation and antibody formation. 
The technical assistance of Ms. Lee Silver is gratefully 
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Discuss ion 
Dr. Andrew S. Wechsler (Richmond, Va.). Did you 
investigate C4a on the chance that the combination ofPF4 
and heparin would activate the extrinsic pathway? 
Dr. Bernabei. No, we did not. 
Dr. Wechsler. Why did you do this in the first place? 
And why does PF4 interact with heparin? What should we 
know about hat? 
Dr. Bernabei. It has been known for quite a while that 
PF4 neutralizes heparin and is possibly amore physiologic 
molecule. However, in the past, isolating PF4 was an 
econornic burden and therefore was not clinically useful. 
However, recently PF4 was developed as an angiogenesis 
inhibitor and a possible powerful cancer oncologic agent. 
With our knowledge of the ability of PF4 to neutralize 
heparin, we speculated that it might be a better alternative 
to protamine. 
Dr. Wechsler. Would it work with heparinoids as well, 
or is it specific for heparin? 
Dr. Bernabei. It is known to neutralize all cornmercially 
available heparins including low molecular weight hepa- 
rin. 
